TWI683811B - 二氫噠嗪-３,５-二酮衍生物 - Google Patents

二氫噠嗪-３,５-二酮衍生物 Download PDF

Info

Publication number
TWI683811B
TWI683811B TW106123450A TW106123450A TWI683811B TW I683811 B TWI683811 B TW I683811B TW 106123450 A TW106123450 A TW 106123450A TW 106123450 A TW106123450 A TW 106123450A TW I683811 B TWI683811 B TW I683811B
Authority
TW
Taiwan
Prior art keywords
group
substituted
alkyl
alkoxy
phenyl
Prior art date
Application number
TW106123450A
Other languages
English (en)
Chinese (zh)
Other versions
TW201741304A (zh
Inventor
大竹義仁
岡本直樹
小野芳幸
柏木浩孝
金原篤
原田武雄
堀伸行
村田佳久
橘一生
田中翔太
野村研一
井出光昭
水口栄作
市田康弘
大友秀一
堀場直
Original Assignee
中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中外製藥股份有限公司 filed Critical 中外製藥股份有限公司
Publication of TW201741304A publication Critical patent/TW201741304A/zh
Application granted granted Critical
Publication of TWI683811B publication Critical patent/TWI683811B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
TW106123450A 2013-03-13 2014-03-13 二氫噠嗪-３,５-二酮衍生物 TWI683811B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013-051082 2013-03-13
JP2013132889 2013-06-25
JP2013-132889 2013-06-25

Publications (2)

Publication Number Publication Date
TW201741304A TW201741304A (zh) 2017-12-01
TWI683811B true TWI683811B (zh) 2020-02-01

Family

ID=51536921

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106123450A TWI683811B (zh) 2013-03-13 2014-03-13 二氫噠嗪-３,５-二酮衍生物
TW103109058A TWI596095B (zh) 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW103109058A TWI596095B (zh) 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivatives

Country Status (29)

Country Link
EP (2) EP2975030B1 (enExample)
JP (2) JP5814488B2 (enExample)
KR (2) KR102072268B1 (enExample)
CN (1) CN105073715B (enExample)
AU (1) AU2014230552B2 (enExample)
BR (1) BR112015022092B1 (enExample)
CA (1) CA2901868C (enExample)
CL (1) CL2015002543A1 (enExample)
CR (1) CR20150505A (enExample)
DK (1) DK2975030T3 (enExample)
ES (1) ES2811126T3 (enExample)
HR (1) HRP20201211T1 (enExample)
HU (1) HUE050577T2 (enExample)
IL (1) IL240825B (enExample)
LT (1) LT2975030T (enExample)
MX (1) MX376532B (enExample)
MY (1) MY174269A (enExample)
NZ (1) NZ711182A (enExample)
PE (1) PE20151535A1 (enExample)
PH (1) PH12015501940B1 (enExample)
PL (1) PL2975030T3 (enExample)
PT (1) PT2975030T (enExample)
RS (1) RS60911B1 (enExample)
RU (1) RU2662832C2 (enExample)
SG (1) SG11201507345RA (enExample)
SI (1) SI2975030T1 (enExample)
TW (2) TWI683811B (enExample)
UA (1) UA118755C2 (enExample)
WO (1) WO2014142273A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI891827B (zh) * 2020-06-26 2025-08-01 日商日本農藥股份有限公司 芳基四氫噠嗪衍生物或其鹽類及含有該化合物的殺蟲劑以及其使用方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5814488B2 (ja) * 2013-03-13 2015-11-17 中外製薬株式会社 ジヒドロピリダジン−３，５−ジオン誘導体
ES2975807T3 (es) * 2014-09-12 2024-07-16 Chugai Pharmaceutical Co Ltd Compuesto farmacéutico que contiene inhibidor del transportador de fosfato dependiente de sodio y adsorbente de fósforo para uso en la prevención, tratamiento o supresión de enfermedad renal crónica, arteriosclerosis asociada con calcificación vascular o calcificación ectópica
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料（常州）有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
WO2022260064A1 (ja) 2021-06-08 2022-12-15 中外製薬株式会社 ジヒドロピリダジン－３，５－ジオン誘導体を含有する製剤
KR20240125659A (ko) 2021-12-28 2024-08-19 니혼노야쿠가부시키가이샤 아릴테트라히드로피리다진 유도체 또는 그의 염류 및 해당 화합물을 함유하는 살충제 그리고 그 사용 방법
CN119212723A (zh) 2022-05-11 2024-12-27 中外制药株式会社 用于治疗或预防囊性疾病的药物组合物
CN116217862A (zh) * 2023-03-21 2023-06-06 中国农业科学院农业环境与可持续发展研究所 一种可降解生物膜助剂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
CN102264740A (zh) * 2008-08-20 2011-11-30 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL372171A1 (en) * 2002-02-19 2005-07-11 Ono Pharmaceutical Co, Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
SG177981A1 (en) * 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
SI2086944T1 (sl) * 2006-11-03 2010-04-30 Basf Se Postopek za pripravo difluorometilpirazolil karboksilatov
CN102869656B (zh) 2010-04-28 2014-03-12 安斯泰来制药株式会社 四氢苯并噻吩化合物
EP2590965B1 (en) * 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EA023955B1 (ru) 2011-10-27 2016-07-29 Астеллас Фарма Инк. Производное аминоалкилзамещенного n-тиенилбензамида
JP5814488B2 (ja) * 2013-03-13 2015-11-17 中外製薬株式会社 ジヒドロピリダジン−３，５−ジオン誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CN102264740A (zh) * 2008-08-20 2011-11-30 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI891827B (zh) * 2020-06-26 2025-08-01 日商日本農藥股份有限公司 芳基四氫噠嗪衍生物或其鹽類及含有該化合物的殺蟲劑以及其使用方法

Also Published As

Publication number Publication date
BR112015022092A2 (pt) 2017-07-18
TW201446756A (zh) 2014-12-16
IL240825A0 (en) 2015-10-29
AU2014230552B2 (en) 2017-11-16
CN105073715B (zh) 2017-12-01
KR20160119282A (ko) 2016-10-12
JPWO2014142273A1 (ja) 2017-02-16
KR102072268B1 (ko) 2020-01-31
CN105073715A (zh) 2015-11-18
EP2975030A4 (en) 2016-08-03
HRP20201211T1 (hr) 2020-11-13
MY174269A (en) 2020-04-01
JP2016040262A (ja) 2016-03-24
HK1212700A1 (zh) 2016-06-17
MX376532B (es) 2025-03-07
RS60911B1 (sr) 2020-11-30
KR101664460B1 (ko) 2016-10-10
AU2014230552A1 (en) 2015-08-13
NZ711182A (en) 2020-05-29
JP6420738B2 (ja) 2018-11-07
SI2975030T1 (sl) 2020-10-30
PH12015501940A1 (en) 2016-01-11
TWI596095B (zh) 2017-08-21
PL2975030T3 (pl) 2021-01-11
WO2014142273A1 (ja) 2014-09-18
CR20150505A (es) 2015-10-26
BR112015022092A8 (pt) 2018-01-23
TW201741304A (zh) 2017-12-01
ES2811126T3 (es) 2021-03-10
PE20151535A1 (es) 2015-10-28
EP2975030A1 (en) 2016-01-20
EP3757093A1 (en) 2020-12-30
SG11201507345RA (en) 2015-10-29
EP2975030B1 (en) 2020-07-15
CL2015002543A1 (es) 2016-02-26
CA2901868A1 (en) 2014-09-18
UA118755C2 (uk) 2019-03-11
IL240825B (en) 2020-07-30
LT2975030T (lt) 2020-09-25
JP5814488B2 (ja) 2015-11-17
MX2015012537A (es) 2016-02-10
PH12015501940B1 (en) 2016-01-11
HUE050577T2 (hu) 2020-12-28
RU2662832C2 (ru) 2018-07-31
CA2901868C (en) 2022-05-03
KR20150127721A (ko) 2015-11-17
RU2015143507A (ru) 2017-04-19
PT2975030T (pt) 2020-09-28
DK2975030T3 (da) 2020-08-31
BR112015022092B1 (pt) 2023-04-11

Similar Documents

Publication Publication Date Title
TWI683811B (zh) 二氫噠嗪-３,５-二酮衍生物
CN107072993B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
JP2020525508A (ja) 線維症の治療のための新規化合物およびその医薬組成物
CN108779115B (zh) 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
KR20240133727A (ko) Nrf2 활성화 작용을 갖는 함질소 헤테로환 화합물
US9499553B2 (en) Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
CN108299436B (zh) 黄嘌呤类化合物及其药物组合物和应用
WO2023274396A1 (zh) 苯并氮杂环类化合物及其在药物中的应用
RU2811864C1 (ru) Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата
HK1235279B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
HK1212700B (en) Dihydropyridazine-3,5-dione derivative
HK1235279A1 (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
WO2025161532A1 (zh) Pde4b抑制剂及其药物组合物和用途